Testing KIO-301 eye injections for advanced retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of retinitis pigmentosa (non-syndromic) or Usher syndrome type II.
- Your vision must be very poor — either no light perception or only light perception up to a certain level.
- You must not have had certain eye surgeries (except cataract surgery more than 12 months ago).
- You must agree to use birth control (if applicable) from screening to 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.